Late Hepatitis B reactivation after treatment with rituximab

There is a large reservoir of individuals with past hepatitis B virus (HBV) infection that are in risk for HBV reactivation when immunosuppressed. On the setting of hematologic malignancy, the malignancy itself and currently used treatments, especially anti-CD20 agents, have risk of HBV reactivation...

Descripción completa

Detalles Bibliográficos
Autores principales: Pereira, Sara Lacerda, Duro, Raquel, Sarmento, António
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761666/
https://www.ncbi.nlm.nih.gov/pubmed/35070716
http://dx.doi.org/10.1016/j.idcr.2022.e01393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8761666/
https://www.ncbi.nlm.nih.gov/pubmed/35070716
http://dx.doi.org/10.1016/j.idcr.2022.e01393

Ejemplares similares